Uveal Melanoma—Clinical and Pathological Update
1. Augsburger JJ, Damato BE, Bornfeld N, Uveal Melanoma. In: Yanoff MD, Duker JS (eds), Ophthalmology, 3rd edn, Mosby Elsevier, 2009;895–905.
2. Kujala E, Makitie T, Kivela T, Very long-term prognosis of patients with malignant uveal melanoma, Invest Ophthalmol Vis Sci, 2003;44(11):4651–9.
3. Singh AD, Topham A, Survival rates with uveal melanoma in the United States: 1973-1997, Ophthalmology, 2003;110(5):962–5.
4. Pantel K, Brakenhoff RH, Dissecting the metastatic cascade, Nat Rev Cancer, 2004;4(6):448–56.
5. Augsburger JJ, Gamel JW, Clinical prognostic factors in patients with posterior uveal malignant melanoma, Cancer, 1990;66(7):1596–600.
6. Mooy CM, De Jong PT, Prognostic parameters in uveal melanoma: a review, Surv Ophthalmol, 1996;41(3):215–28.
7. Augsburger JJ, Schroeder RP, Territo C, et al., Clinical parameters predictive of enlargement of melanocytic choroidal lesions, Br J Ophthalmol, 1989;73(11):911–7.
8. Seddon JM, Polivogianis L, Hsieh CC, et al., Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors, Arch Ophthalmol, 1987;105(6):801–6.
9. Scholes AG, Damato BE, Nunn J, et al., Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival, Invest Ophthalmol Vis Sci, 2003;44(3):1008–11.
10. Horsman DE, Sroka H, Rootman J, White VA, Monosomy 3 and isochromosome 8q in a uveal melanoma, Cancer Genet Cytogenet, 1990;45(2):249–53.
11. Sisley K, Rennie IG, Cottam DW, et al., Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8, Genes Chromosomes Cancer, 1990;2(3):205–9.
12. Harbour JW, Molecular prognostic testing in uveal melanoma: has it finally come of age?, Arch Ophthalmol, 2007;125(8):1122–3.
13. Ehlers JP, Worley L, Onken MD, Harbour JW, Integrative genomic analysis of aneuploidy in uveal melanoma, Clin Cancer Res, 2008;14(1):115–22.
14. Augsburger JJ, Correa ZM, Schneider S, et al., Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category, Trans Am Ophthalmol Soc, 2002;100:225–32; discussion 232–4.
15. Tschentscher F, Husing J, Holter T, et al., Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities, Cancer Res, 2003;63(10):2578–84.
16. Onken MD, Worley LA, Harbour JW, A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis, Clin Cancer Res, 2008;14(12):3737–45.
17. Onken M, Worley LA, Long MD, et al., Oncogenic mutations in GNAQ occur early in uveal melanoma, Invest Ophthalmol Vis Sci, 2008;49(12):5230–4.
18. Mocellin S, Rossi CR, The melanoma molecular map project, Melanoma Res, 2008;18(3):163–5.
19. Woll E, Bedikian A, Legha SS, Uveal melanoma: natural history and treatment options for metastatic disease, Melanoma Res, 1999;9(6):575–81.
20. Augsburger JJ, Corrêa ZM, Shaikh AH, Quality of evidence about effectiveness of treatments for metastatic uveal melanoma, Trans Am Ophthalmol Soc, 2008;106:128–35; discussion 135–7.
21. Rivoire M, Kodjikian L, Baldo S, et al., Treatment of liver metastases from uveal melanoma, Ann Surg Oncol, 2005;12(6):422–8.
22. Bedikian AY, Legha SS, Mavligit G, et al., Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors, Cancer, 1995;76(9):1665–70.
23. Fong Y, Fortner J, Sun RL, et al., Clinical score for predicting
recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases, Ann Surg, 1999;230(3):309–18; discussion 318-21.
24. Pereira PR, Odashiro AN, Marshall JC, et al., The role of c-kit and imatinib mesylate in uveal melanoma, J Carcinog, 2005;4:19.
25. Kadenhe-Chiweshe A, Papa J, McCrudden KW, et al., Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation, Mol Cancer Res, 2008;6(1):1–9.
26. Wedge SR, Kendrew J, Hennequin LF, et al., AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer, Cancer Res, 2005;65(10):4389–400.
27. Diener-West M, Reynolds SM, Agugliaro DJ, et al., Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26, Arch Ophthalmol, 2005;123(12):1639–43.
28. Diener-West M, Reynolds SM, Agugliaro DJ, et al., Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23, J Clin Oncol, 2004;22(12):2438–44.
29. Kaiserman I, Amer R, Pe’er J, Liver function tests in metastatic uveal melanoma, Am J Ophthalmol, 2004;137(2):236–43.
30. Eskelin S, Pyrhonen S, Summanen P, et al., Screening for metastatic malignant melanoma of the uvea revisited, Cancer, 1999;85(5):1151–9.
31. Rietschel P, Panageas KS, Hanlon C, et al., Variates of survival in metastatic uveal melanoma, J Clin Oncol, 2005;23(31):8076–80.
32. Maeda T, Tateishi U, Suzuki S, et al., Magnetic resonance screening trial for hepatic metastasis in patients with locally controlled choroidal melanoma, Jpn J Clin Oncol, 2007;37(4):282–6.
US OPHTHALMIC REVIEW
61
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76